Autopsy report · NCT03137706

Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer

“Insufficient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 3 years 11 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

University of Southern California

Sponsor type

University, hospital or other

Conditions

Colon Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Pancreatic Carcinoma

Interventions

Biospecimen Collection; Laboratory Biomarker Analysis; Laboratory Procedure

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
  “failure to accrue” (89% match in meaning)
• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
  “insufficient accrual rate” (85% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (84% match in meaning)
• Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
  “insufficient rate of accrual” (83% match in meaning)
• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
  “unable to accrue” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.